Your browser doesn't support javascript.
loading
BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.
van Not, Olivier J; Blokx, Willeke A M; van den Eertwegh, Alfons J M; de Meza, Melissa M; Haanen, John B; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Rozemarijn S; Stevense-den Boer, Marion; van der Veldt, Astrid A M; Boers-Sonderen, Marye J; Jansen, Anne M L; Wouters, Michel W J M; Suijkerbuijk, Karijn P M.
Afiliação
  • van Not OJ; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
  • Blokx WAM; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • van den Eertwegh AJM; Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • de Meza MM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Haanen JB; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
  • Blank CU; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands.
  • Aarts MJB; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van den Berkmortel FWPJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • de Groot JWB; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hospers GAP; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Kapiteijn E; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Piersma D; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen, the Netherlands.
  • van Rijn RS; Isala Oncology Center, Isala, Zwolle, the Netherlands.
  • Stevense-den Boer M; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
  • van der Veldt AAM; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Boers-Sonderen MJ; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.
  • Jansen AML; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
  • Wouters MWJM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands.
  • Suijkerbuijk KPM; Department of Medical Oncology and Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.
JCO Precis Oncol ; 6: e2200018, 2022 Sep.
Article em En | MEDLINE | ID: mdl-36130145
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article